Abdominal Aortic Aneurysm Treatment Market By Treatment Type (Endovascular Aneurysm Repair, Open Surgical Repair); By Product Type (Stent Grafts, Catheters & Guidewires, Closure Devices & Balloons, Surgical Instruments); By End User (Hospitals & Surgical Centers, Outpatient Vascular Clinics, Military/Trauma Units); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Abdominal Aortic Aneurysm Treatment Market is projected to reach $ 5.70 billion by 2030 , growing from an estimated $ 3.5 billion in 2024 , with a CAGR of 8.6% during the forecast period (2024–2030), based on Strategic Market Research.

 

Abdominal aortic aneurysm (AAA) is a localized enlargement of the abdominal aorta that can rupture without warning, often resulting in fatal outcomes. It typically affects individuals over 65 years of age, with smoking, hypertension, and atherosclerosis being the leading risk factors. Because most AAAs remain asymptomatic until they rupture, the treatment market revolves heavily around pre-rupture interventions — both surgical and endovascular.

 

The strategic importance of AAA treatment is growing for a few reasons. First, global life expectancy is increasing, bringing age-related vascular conditions into sharper focus. Second, health systems are making aneurysm screening programs more routine — especially in high-risk male populations over 65. These initiatives are catching aneurysms earlier and driving demand for elective (rather than emergency) treatment.

 

Technology is shifting the treatment landscape. Endovascular aneurysm repair (EVAR) has largely overtaken open surgical repair in many developed nations due to its lower morbidity and shorter recovery times. Meanwhile, next-gen stent grafts, drug-eluting technologies, and real-time imaging guidance are reducing complications and reintervention rates. In parallel, AI-assisted image analysis is helping vascular surgeons assess rupture risk more accurately.

 

The stakeholder ecosystem is highly technical. Medical device companies dominate the space with advanced graft and catheter technologies. Vascular surgeons and interventional radiologists are the primary clinical users. Hospitals and surgical centers act as procurement decision-makers. And regulatory bodies play a strong role, especially in approving device iterations and post-market surveillance.

 

Interestingly, the AAA treatment market is now seeing attention from health insurers and policymakers too — largely because elective EVAR can be far more cost-effective than emergency surgery after rupture. That’s nudging governments in Europe and parts of Asia to subsidize population-level screening.

 

This is no longer a niche surgical problem — it’s a systemic, preventative care challenge. And the players who solve for long-term monitoring, precision interventions, and better patient selection will drive the next phase of growth.

 

Market Segmentation And Forecast Scope

The abdominal aortic aneurysm treatment market is structured around four major axes: Treatment Type, Product Type, End User, and Geography. Each segment reflects a different aspect of how clinicians approach aneurysm repair, and how manufacturers align their offerings with surgical trends, regulatory preferences, and reimbursement models.

By Treatment Type

Endovascular Aneurysm Repair (EVAR)
This is the dominant treatment option, especially in high-income countries. EVAR is minimally invasive and involves placing a stent graft via catheter inside the aneurysm to reinforce the aortic wall. In 2024, EVAR is expected to account for over 60% of total procedures due to its lower perioperative risk and shorter hospital stays.

Open Surgical Repair (OSR)
Still relevant for younger patients, anatomically complex cases, and when EVAR isn’t feasible. However, its use is declining due to its invasiveness, longer recovery, and higher immediate risk. That said, some vascular surgeons argue OSR offers better long-term durability — particularly in patients with a long life expectancy.

 

By Product Type

Stent Grafts
These are the centerpiece of EVAR procedures. Innovation is accelerating in modular, fenestrated, and branched designs to accommodate diverse aortic anatomies. Demand for next-gen grafts — with lower migration and better sealing performance — is steadily rising.

Catheters and Guidewires
Essential for device delivery and placement. These are often bundled into procedure kits. High-quality navigation and flexibility matter most in tortuous anatomies.

Closure Devices & Balloons
Used post-procedure or during graft deployment. Their adoption is highly protocol-driven, and uptake tends to be higher in advanced surgical centers .

Surgical Instruments
Still relevant for open repair, particularly in markets where EVAR infrastructure is limited. Demand remains steady in teaching hospitals and trauma units.

 

By End User

Hospitals and Surgical Centers
Account for the lion’s share of procedure volume. Academic medical centers are early adopters of complex EVAR systems, while mid-sized hospitals focus on routine AAA repairs.

Outpatient Vascular Clinics
These are emerging, especially in the U.S., where office-based labs (OBLs) are increasingly performing elective EVARs. Reimbursement changes could accelerate this trend over the next five years.

 

By Region

North America and Europe lead in adoption due to widespread AAA screening programs, specialist availability, and regulatory approval of advanced graft designs.

Asia Pacific is the fastest-growing region, driven by rising life expectancy, cardiovascular screening, and infrastructure upgrades — particularly in China, South Korea, and India.

Latin America, Middle East & Africa (LAMEA) still lags in terms of EVAR penetration. But select countries like Brazil, UAE, and South Africa are investing in vascular care modernization.

Among all these segments, EVAR stands out as the growth engine — but not just because it's safer. It’s because health systems are starting to view it as a cost-containment strategy in managing older, high-risk patients.

 

Market Trends And Innovation Landscape

The abdominal aortic aneurysm (AAA) treatment market is entering a high-tech phase — not just in terms of devices, but in how those devices are being integrated into broader vascular care pathways. Several trends are converging to redefine the treatment model: device personalization, imaging intelligence, long-term monitoring, and value-based surgical planning.

Endografts Are Getting Smarter and More Flexible

Traditional stent grafts worked well for textbook anatomies — straight vessels, wide landing zones, minimal angulation. But that’s not the real world. Now, manufacturers are pushing out fenestrated and branched EVAR systems that can treat aneurysms closer to the renal arteries or with complex shapes.

More importantly, off-the-shelf grafts with modular customization are replacing highly delayed custom designs. That’s shortening procedural planning time from weeks to days — critical in semi-urgent cases. One vascular surgeon noted that “we’ve gone from choosing patients to fit the graft, to designing grafts that flex to fit the patient.”

 

Imaging and AI Are Changing Pre- and Post-Op Care

CT angiography remains the standard for AAA planning, but AI is making it smarter. Algorithms are now being used to:

• Automate diameter and growth measurements

• Identify complex neck angulation

• Predict rupture risk based on wall stress modeling

Post-surgery, AI tools can flag subtle endoleaks or migration in follow-up imaging — long before a radiologist would normally intervene. Some EVAR platforms now integrate directly with these image-analysis tools, offering real-time feedback during and after the procedure.

This is especially relevant for low-volume centers where specialized vascular imaging expertise may not be on hand every day.

 

Remote Monitoring Is Emerging for EVAR Patients

One of the quieter innovations? Implantable sensors and wearable tech to monitor AAA status post-repair. These tools are still in pilot phase but could drastically reduce the number of surveillance CT scans — a major cost and radiation concern.

Some early-stage companies are developing pressure sensors embedded in the graft to monitor sac expansion and flow anomalies. Think of it as a smart graft that alerts the surgeon, not the patient.

 

Automation and Robotics Are Finding Their Place

Robotic catheter navigation is being tested in high-volume vascular centers , primarily for complex EVAR. These systems aim to:

• Reduce operator fatigue

• Improve precision in tortuous anatomies

• Shorten fluoroscopy time

So far, adoption is limited due to cost and training requirements. But in hybrid operating rooms, particularly in Europe and Japan, robotic assistance is starting to gain attention.

 

Partnerships Are Driving Integrated EVAR Platforms

It’s not just device innovation anymore. Major vendors are collaborating with imaging software companies, AI startups , and even hospital groups to co-create end-to-end EVAR platforms. These ecosystems typically include:

• Preoperative planning software

• Intraoperative imaging integration

• Predictive analytics for outcomes tracking

This vertical integration model is helping hospitals streamline procurement and unify workflows — a big selling point for cash-strapped surgical departments.

Bottom line: the technology race in AAA isn’t about flashy features — it’s about lowering failure rates, reducing follow-up imaging, and making high-precision EVAR accessible to more centers . The winners will be those who solve for real-world anatomy and real-world hospital constraints.

 

Competitive Intelligence And Benchmarking

The abdominal aortic aneurysm treatment market is dominated by a handful of global medtech firms, with each player carving out a niche based on device innovation, training support, and geographic reach. What’s interesting is how these companies are increasingly shifting from product suppliers to platform partners — offering surgical planning tools, follow-up software, and hybrid OR integration as part of their portfolio.

Medtronic

As one of the earliest and most dominant players in EVAR, Medtronic continues to lead in terms of installed base and brand recognition. Its strategy focuses on modular graft systems that can address a wide range of anatomies without waiting for custom manufacturing. The company is also doubling down on long-term surveillance capabilities, partnering with imaging analytics firms to offer post-EVAR follow-up solutions.

Medtronic’s strength lies in its global reach — with strong adoption across North America, Europe, and parts of Asia-Pacific.

 

Cook Medical

Cook Medical holds a strong position in complex aneurysm repair, particularly with its fenestrated and branched stent grafts. Its emphasis on customizability has made it a preferred choice in cases involving short necks or irregular anatomies. However, turnaround time for custom grafts has historically been a challenge.

That said, the company is investing heavily in semi-custom designs and manufacturing automation to speed up delivery — a crucial advantage for treating expanding aneurysms that can't wait.

 

W. L. Gore & Associates

Gore stands out for its focus on durability and ease of use, especially in community hospitals and mid-volume centers . Its grafts are known for strong conformability and low complication rates. While it hasn’t been as aggressive in AI integration, Gore has prioritized surgeon education, with a global training program that's helped it build loyalty across a broad surgeon base.

The company’s consistent messaging around reliability has made it a go-to for elective EVAR in both the U.S. and select European markets.

 

Terumo Aortic

Terumo Aortic brings strength in thoracoabdominal and arch segment repairs — a more complex subset of aneurysms. While not as dominant in infrarenal AAA, its presence is growing due to high-end procedural capabilities and integration with cardiac surgery platforms.

Terumo’s strategy is often hospital-specific: targeting large teaching centers and hybrid ORs where both cardiac and vascular teams operate. Their appeal lies in cross-specialty collaboration rather than mass-market scale.

 

Endologix

Endologix focuses on novel EVAR systems for patients with challenging anatomies. Its designs aim to overcome limitations in neck sealing and migration — key causes of long-term failure. The company’s Alto system, for instance, is designed to reduce the need for precise sizing and enable faster deployment.

While Endologix is smaller than the big three, its niche focus makes it attractive in geographies where off-label EVAR use is common, or where traditional devices aren’t delivering consistent outcomes.

 

Boston Scientific (watchlist)

Although Boston Scientific is not a major player yet in AAA, recent M&A activity in peripheral interventions and vascular access suggests it may expand into the space. Its acquisition of Lumenis and increased focus on image-guided therapies makes it a company to watch.

If Boston Scientific does enter the AAA space directly, it’s likely to be through a tech-heavy angle — combining imaging, delivery systems, and post-op tracking.

In this market, product performance alone isn’t enough. Players that offer full procedural ecosystems, including planning tools, AI-based monitoring, and surgeon training, are quickly outpacing those with stand-alone grafts. We're now in a phase where platforms matter more than products.

 

Regional Landscape And Adoption Outlook

Adoption of abdominal aortic aneurysm (AAA) treatment varies dramatically across regions — not just in procedure volume, but in the type of interventions offered, availability of advanced grafts, and patient access to vascular care. What’s clear is that regional policy, screening infrastructure, and healthcare financing have just as much impact as surgical innovation when it comes to treatment rates.

North America

North America, especially the United States, remains the largest market for AAA treatment — driven by high awareness, routine screening for high-risk populations, and wide access to advanced EVAR systems. Medicare coverage for AAA screening (for men aged 65–75 with a history of smoking) has helped with early detection, pushing more aneurysms into the elective repair category, where EVAR dominates.

Hospitals in the U.S. are also more likely to invest in hybrid operating rooms and advanced imaging tools — giving surgeons the infrastructure to handle complex aneurysm anatomies.

Canada follows a similar clinical trend but with more centralized healthcare decisions. Adoption of EVAR is strong in urban centers , while rural areas rely more heavily on referral systems to tertiary hospitals.

 

Europe

Europe has historically been more conservative in adopting new vascular technologies, but that’s changing fast. Countries like Germany, the UK, and France have standardized AAA screening for men over 65, similar to the U.S. As a result, elective EVAR volumes are rising steadily.

In Scandinavia, where registry data is strong, outcomes for EVAR and open repair are closely monitored — and public reporting incentivizes hospitals to adopt best practices. That data-driven environment has made Europe a hotspot for clinical trials and early adoption of AI-driven planning tools.

That said, Southern and Eastern Europe still face challenges with training access and reimbursement delays, which slows EVAR adoption outside of capital cities.

 

Asia Pacific

Asia Pacific is the fastest-growing region, but the baseline is lower due to historically limited screening and delayed diagnosis. That’s changing. Countries like Japan, South Korea, and increasingly China, are investing in vascular surgery capacity and upgrading surgical infrastructure.

Japan has a strong tradition of minimally invasive surgery, and EVAR has been widely adopted in large hospitals. South Korea’s national insurance system is starting to reimburse more endovascular procedures — boosting volume. China’s story is different: rapid urbanization and aging demographics are expanding the patient pool, but access to EVAR is still centered in tier-1 hospitals.

India and Southeast Asia remain in the early growth phase. Here, cost is a critical barrier — and open surgery is still the default in many public hospitals.

 

Latin America

AAA treatment in Latin America is mostly limited to large private hospitals and academic medical centers . Brazil is the regional leader in both EVAR procedures and availability of advanced grafts. Public system access, however, is still limited. Smaller markets like Argentina, Chile, and Colombia are showing sporadic growth, usually around urban centers .

A major constraint here is lack of reimbursement for newer devices and long supply chain lead times for custom grafts.

 

Middle East & Africa (MEA)

The MEA region is highly fragmented. In the Gulf countries like UAE and Saudi Arabia, there’s growing investment in vascular surgery programs — with private hospitals importing EVAR systems and recruiting Western-trained surgeons. However, in most of Africa, AAA often goes undiagnosed or is treated only in emergencies due to a lack of vascular screening and interventional capacity.

That said, some countries like South Africa are starting to invest in hybrid ORs and training partnerships, slowly increasing procedure capabilities.

In short, EVAR is accelerating, but access is unequal. The next decade is likely to see major progress in Asia and parts of Latin America, where public health initiatives, private investment, and training programs are converging to unlock demand.

 

End-User Dynamics And Use Case

The adoption and impact of abdominal aortic aneurysm (AAA) treatments — particularly endovascular approaches — vary significantly depending on the type of end user. From high-volume academic centers to smaller surgical units and outpatient vascular clinics, each setting brings unique constraints and opportunities to the table. Understanding how these institutions deploy AAA treatment tools helps clarify where innovation sticks and where it stalls.

Hospitals and Surgical Centers

Tertiary care hospitals and academic medical centers are the backbone of AAA treatment globally. These institutions typically house vascular surgery departments, hybrid ORs, and the diagnostic infrastructure required for screening and follow-up. They are also the primary adopters of complex EVAR systems — particularly branched and fenestrated stent grafts.

In high-income regions like the U.S., Germany, and Japan, hospitals regularly perform elective EVAR procedures and have access to planning software, AI-driven image analysis, and on-demand custom grafts. In lower-resource settings, hospitals are still more likely to conduct open surgical repairs, especially for ruptured AAAs.

Procurement in these settings is often dictated by value-based care metrics: how many reinterventions were avoided, how quickly patients were discharged, and whether the graft reduced long-term surveillance needs. That’s made post-op device performance a key differentiator among vendors.

 

Outpatient Vascular Clinics and Office-Based Labs (OBLs)

A rising share of elective EVARs is being performed in office-based vascular centers , particularly in the U.S. This shift is driven by changes in reimbursement models, physician ownership trends, and better portability of imaging and delivery systems.

These facilities focus on low-to-moderate complexity cases and typically opt for off-the-shelf EVAR grafts with simple deployment mechanisms. Since OBLs are leaner in staff and imaging infrastructure, device selection heavily favors ease of use and procedural speed.

One vascular clinic in Texas, for example, transitioned 40% of their elective AAA cases from hospital ORs to office-based suites, cutting facility costs by over 30% while maintaining outcomes.

However, these centers still refer complex cases to hospitals — especially those requiring custom grafts, hybrid imaging, or ICU backup.

 

Military and Emergency Response Units

In military hospitals and trauma centers , ruptured AAA cases are still a significant challenge. While not routine, EVAR systems with fast-deployment kits and low-profile catheters are starting to be included in trauma protocols — particularly in battlefield medicine or for older veterans in the VA system.

These units prioritize portability, rapid deployment, and minimal fluoroscopy, and are often testing grounds for next-gen device platforms under FDA humanitarian device exemptions (HDE).

 

Specialty Clinics and Diagnostic Centers

While not directly involved in interventions, vascular imaging clinics play a growing role in the AAA ecosystem. These centers conduct the initial diagnosis using ultrasound or CT angiography, often feeding patients into the surgical pipeline. The increasing use of AI-based triage tools in these clinics is expected to boost early detection rates — especially in asymptomatic cases.

 

Use Case Highlight: Real-World Workflow Shift in South Korea

A tertiary hospital in Busan, South Korea, implemented a screen-to-treat program in partnership with a vascular imaging startup and a local EVAR device distributor. Male patients over 65 undergoing unrelated imaging were flagged for aneurysm screening. If an AAA >5.5 cm was detected, patients were routed through a fast-track system into the vascular surgery team.

By combining AI image review, standardized pre-op planning, and off-the-shelf stent grafts, the hospital reduced the average time from diagnosis to repair from 27 days to 9 days. Clinical outcomes improved, and bed utilization dropped by 15% due to same-day discharges for elective EVAR.

Across settings, the common thread is clear: AAA treatment is moving from an emergency intervention to a planned, optimized, and increasingly outpatient procedure . The institutions that streamline this shift — with the right mix of tech, training, and triage — are shaping the future of vascular care.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 years)

• Medtronic launched an enhanced version of its EVAR system with integrated sac sealing technology designed to reduce Type II endoleaks and the need for reinterventions.

• Cook Medical announced the expansion of its U.S.-based manufacturing facility to accelerate production of custom and semi-custom fenestrated grafts.

• Gore received CE Mark approval for its low-profile Excluder conformable device, which improves sealing in tortuous anatomies common in elderly patients.

• Terumo Aortic launched a digital planning platform integrated with its endograft line, enabling vascular surgeons to simulate complex deployments.

• A U.S.-based startup received funding to develop an implantable pressure sensor that tracks sac expansion post-EVAR, potentially eliminating the need for frequent CT scans.

 

Opportunities

• AI-enhanced imaging and diagnostics : Early adoption of AI tools in AAA detection, rupture risk modeling , and post-procedure surveillance could lower costs and improve outcomes — especially in low-volume hospitals.

• Emergence of office-based EVAR : The shift toward outpatient vascular centers and office-based labs in the U.S. opens a growth path for device makers focused on simple, fast-deployment systems.

• Rising adoption in Asia-Pacific : Growing public health investments and infrastructure upgrades in China, South Korea, and India are laying the foundation for faster EVAR adoption in high-volume markets.

 

Restraints

• Reimbursement disparities : Many middle-income countries lack adequate coverage for endovascular procedures, limiting access to advanced AAA treatment — particularly in public hospitals.

• Limited surgeon training in emerging markets : The learning curve for complex EVAR techniques remains steep. Without dedicated training programs and mentorship pipelines, device adoption in certain regions will lag.
   

The path forward will depend on simplifying complex procedures, digitizing surgical workflows, and supporting long-term follow-up — not just selling devices. Players who embrace that broader view will be the ones who win market share in the next cycle.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 3.5 Billion
Revenue Forecast in 2030	USD 5.70 Billion
Overall Growth Rate	CAGR of 8.6% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Treatment Type, By Product Type, By End User, By Geography
By Treatment Type	Endovascular Aneurysm Repair (EVAR), Open Surgical Repair (OSR)
By Product Type	Stent Grafts, Catheters & Guidewires, Closure Devices & Balloons, Surgical Instruments
By End User	Hospitals & Surgical Centers, Outpatient Vascular Clinics, Military/Trauma Units
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, UK, France, Japan, China, India, Brazil, South Korea, UAE
Market Drivers	- Increasing use of EVAR for elective repairs - Expanding AAA screening programs in aging populations - AI-driven imaging and post-EVAR surveillance tools
Customization Option	Available upon request